Full protection against subcutaneous and aerosol challenge in mice
USAMRIID at Fort Detrick, reported in 2021. Two other ways of weakening CO92: removing the pigmentation locus or the pPst plasmid, and deleting yscN, which the type III secretion system needs. The briefing records full protection of mice after both an injection under the skin and an aerosol challenge. Still preclinical. The laboratory is Department of Defense, not a public company.
Preclinical · aerosol. Phase 3 is empty here, as it is for every programme in the set.
A mark at 2021. Labelled “2021” on the briefing. Not a forecast.
Analyst card
- Mice. Protection after a subcutaneous injection and after an aerosol. Septicemic disease is not separated.
- Not reported. These are live CO92 derivatives, not an antigen pick-list.
- None.
- Not stated.
- Formulation and cold-chain requirement are not stated.
- Not reported. No time-to-protection figure is in the briefing.
- Plague only.
- Full protection of mice on both routes, reported in 2021. Challenge dose is not restated.
- Mouse data. Not an Animal Rule file. No primate result is recorded for this construct.
Pipeline record
- USAMRIID, Fort Detrick. Department of Defense, not a public company.
- CO92 missing the pigmentation locus or the pPst plasmid, and a separate construct missing yscN.
- The type III secretion system needs it. Without it the bacterium cannot inject its usual toxins.
- Full protection of mice after a subcutaneous injection and after an aerosol. Reported in 2021. Still preclinical.
News
Checking today’s headlines.
Latest intel
Checking Europe PMC.
PubMed
Checking today’s index.
- Live attenuated
A weakened whole bacterium, not a purified protein. EV76 is the long-standing example; newer constructs delete extra virulence genes and are still in animals.
- US — USAMRIID, Fort Detrick
- United States
- Aerosol and subcutaneous · mice
- Preclinical · aerosol
- 2021
- Whole organism